Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AXYS Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (271)	5/26/1999 12:03:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 455

Yeah.... I feel that there are many psoriasis programs that have a better chance of markedly impacting the disease, of striking at a central causative effect rather than resolution of symptoms.

To: LLCF who wrote (271)	5/26/1999 7:08:00 PM
From: David Bogdanoff	Read Replies (1) \| Respond to of 455

DK; I asked about the psoriasis program at today's annual shareholder's meeting. It was picked because of lack of effective current therapies and a belief that the inflamatory lesions are mediated by mast cells which can be controlled their technology platform. The studies are in fact on the small size, around 30 patients and allow for a quick termination of the program if their is a low response rate. I note that Sugen recently had to terminate their psoriasis program. From comments at today's meeting, there seems to be a lack of concensus as the the cause of the disease. Of course, if a permanent cure were found, palliative therapy would become obsolete. David